trending Market Intelligence /marketintelligence/en/news-insights/trending/ex8r8PEtDuWHFrK3yBs_6A2 content esgSubNav
In This List

Johnson & Johnson increases US prices of 2 dozen prescription drugs

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Johnson & Johnson increases US prices of 2 dozen prescription drugs

Johnson & Johnson raised U.S. list prices of about two dozen drugs, including some of its top-selling products, Reuters reported.

According to the report, data from Rx Savings Solutions, which sells software to help employers and health plans choose the least expensive medicines, indicated that most of the increases were between 6% and 7%.

Psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto are now among the hundreds of medicines to undergo price hikes at the start of 2019.

Johnson & Johnson said that although price increases on its medicines will average 4.2% in 2019, it expects to receive a lower net price for the therapies due to rebates and discounts it will negotiate with payers.

New Brunswick, N.J.-based J&J, the world's largest pharmaceutical company, has no plans to hike prices on any more drugs this year, according to spokesman Ernie Knewitz.